EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-world clinical experience with upadacitinib in a cohort of Italian patients with axial spondyloarthritis

Roberta Ramonda, Mariagrazia Lorenzin, Antonio Carletto, Maria Sole Chimenti, Maria Manara, Giacomo Cozzi, Alen Zabotti, Roberta Foti, Antonio Carriero, Ariela Hoxha, Carlo Selmi, Bernd Raffeiner und 13 weitere

Frontiers in Pharmacology · 29.04.2026 · 17

DOI: 10.3389/fphar.2026.1757110 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.04.2026. Verfasst von Roberta Ramonda und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine DIMED, Rheumatology Unit, Padova University Hospital, Padova, Italy. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There is currently scarce data on the real-world effectiveness and safety of upadacitinib in patients with axial spondyloarthritis (axSpA). This study evaluated clinical outcomes and drug retention rate (DRR) at 6, 12, and 24 months in patients initiating upadacitinib for axSpA.

Methods

This prospective, observational study enrolled consecutive patients with radiographic axSpA (r-axSpA) or non-radiographic axSpA (nr-axSpA) initiating upadacitinib between December 2022 and January 2025 at 16 Italian centres. The primary endpoints were treatment effectiveness—evaluated using clinimetric indices, including the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS) — safety and DRR at 6, 12, and 24 months.

Results

Overall, 203 patients were analysed (48% male; median age at diagnosis 44 years; 22.7% HLA-B27 positive; 71% with nr-axSpA). Sixty-three patients completed the 24-month follow-up. Upadacitinib demonstrated a statistically significant improvement in effectiveness outcomes at 6 months vs. baseline, which was sustained at 12 and 24 months, regardless of previous biologic therapy lines, axSpA subtype, or sex. Furthermore, DRR was 92%, 80%, and 55% at six, 12, and 24 months, respectively. Forty patients discontinued upadacitinib, including 22 for insufficient effectiveness and two for AEs. Twenty-two patients developed infections.

Conclusion

Upadacitinib demonstrated a favourable effectiveness profile in the evaluable axSpA population with sustained remission and high treatment retention over a two-year follow-up. Within the limitations inherent to this observational study, the tolerability profile of upadacitinib was generally consistent with that reported in randomized controlled trials, and no new safety signals were identified. Overall, these findings support the effectiveness of Janus kinase inhibitors in the treatment of patients with axSpA.

Schlagwörter

Stichwörter der Autor:innen

Janus kinase inhibitorsaxial spondylarthritisbiologicsdrug retention ratereal-world evidence (RWE)upadacitinib

Autor:innen und Institutionen

  • Department of Medicine DIMED, Rheumatology Unit, Padova University Hospital, Padova, Italy.
  • Department of Surgery, Oncology and Gastroenterology (DiSCOG), Padova University Hospital, Padova, Italy.
  • Department of Medicine, Rheumatology Unit, AOUI University of Verona, Verona, Italy.
  • Department of Systems Medicine, Rheumatology, Allergology and Clinical Immunology, University of Rome Tor Vergata, Rome, Italy.
  • Department of Rheumatology, ASST Gaetano Pini-CTO, Milan, Italy.
  • Department of Medicine, Rheumatology Division, University of Udine and Azienda Sanitaria Universitaria del Friuli Centrale, Udine, Italy.

Förderung

  • AbbVie

Zitieren

APA

Ramonda, R., Lorenzin, M., Carletto, A., Chimenti, M. S., Manara, M., Cozzi, G., Zabotti, A., Foti, R., Carriero, A., Hoxha, A., Selmi, C., Raffeiner, B., Giollo, A., Cauli, A., Salvarani, C., Atzeni, F., Rossini, M., Fassio, A., Nava, F., …, & Gentileschi, S. (2026). Real-world clinical experience with upadacitinib in a cohort of Italian patients with axial spondyloarthritis. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1757110

Vancouver

Ramonda R, Lorenzin M, Carletto A, Chimenti MS, Manara M, Cozzi G, et al. Real-world clinical experience with upadacitinib in a cohort of Italian patients with axial spondyloarthritis. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1757110

BibTeX
@article{Ramonda2026,
  author = {Ramonda, Roberta and Lorenzin, Mariagrazia and Carletto, Antonio and Chimenti, Maria Sole and Manara, Maria and Cozzi, Giacomo and Zabotti, Alen and Foti, Roberta and Carriero, Antonio and Hoxha, Ariela and Selmi, Carlo and Raffeiner, Bernd and Giollo, Alessandro and Cauli, Alberto and Salvarani, Carlo and Atzeni, Fabiola and Rossini, Maurizio and Fassio, Angelo and Nava, Francesca and Paci, Valentino and Moroncini, Gianluca and Buonanno, Simona and Frediani, Bruno and Luchetti Gentiloni, Michele Maria and Gentileschi, Stefano},
  title = {Real-world clinical experience with upadacitinib in a cohort of Italian patients with axial spondyloarthritis},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1757110}
}
Kostenlos starten →